ACE-inhibitors
Boehringer denies Micardis cancer link
June 14, 2010Sales and Marketing ACE-inhibitors, ARB, Boehringer, Micardis, drug safety
Boehringer Ingelheim has given a robust rebuttal to a Lancet report implicating its hypertension drug Micardis (telmisartan) in scares about …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
